INCYTE CORPORATION

INCY US45337C1027

🆔
Registration No.
3603180
💰
Capitalization
Large-cap

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

🔗
Website
Annual Performance 1
2021 2022 2023 2024 2025
-15% 9% -21% 6% 0%
Annual Insiders Turnover, USD 2

1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);

Insider Activity
📊
Transactions
56
🙍
Insiders
6
Person Price Shares Total Published Completed
Denton Sheila A.
EX VP 		85.54
USD 		3,501
Sold 		299,476
USD 		02/10/2025 03/10/2025
Denton Sheila A.
EX VP 		85.54
USD 		3,501
Sold 		299,476
USD 		02/10/2025 03/10/2025
Denton Sheila A.
EX VP 		87.65
USD 		599
Sold 		52,502
USD 		02/10/2025 02/10/2025
Denton Sheila A.
EX VP 		87.65
USD 		599
Sold 		52,502
USD 		02/10/2025 02/10/2025
Denton Sheila A.
EX VP 		87.65
USD 		599
Sold 		52,502
USD 		02/10/2025 02/10/2025
Denton Sheila A.
EX VP 		87.65
USD 		599
Sold 		52,502
USD 		02/10/2025 02/10/2025
Denton Sheila A.
EX VP 		83.15
USD 		278
Sold 		23,116
USD 		16/09/2025 16/09/2025
Denton Sheila A.
EX VP 		84.97
USD 		598
Sold 		50,812
USD 		02/09/2025 02/09/2025
Denton Sheila A.
EX VP 		86.81
USD 		277
Sold 		24,046
USD 		15/08/2025 15/08/2025
Denton Sheila A.
EX VP 		75.77
USD 		598
Sold 		45,310
USD 		04/08/2025 04/08/2025

Integrated EOD Stock Data and Insider Transactions Chart

Sign in or subscribe to include INCYTE CORPORATION to your watchlist and receive automatic alerts for upcoming transactions.

The visibility of insider buy and sell transactions on this chart should not be the sole factor in your decision to buy or sell a particular stock. Always consider the following dynamic reports for a broader understanding of stock market activities:

 

Historical Performance
1M 3M 6M 1Y 3Y 5Y All Time
5% 2% 19% 13% -32% -50% -33%
Last 52W Low 52W High All-Time Low All-Time High β
87.17 55.17 87.23 55.17 87.23
Company Insiders
Person / Entity Transactions Turnover, USD Average, USD First Last
Flannelly Barry P 11 4,274,332.80 388,575.71 12/06/2024 16/07/2025
Stein Steven H 5 3,359,690.15 671,938.03 03/01/2024 21/07/2025
Denton Sheila A. 19 2,653,129.11 139,638.37 26/02/2025 03/10/2025
Iyengar Vijay K 8 2,324,917.18 290,614.65 02/01/2024 16/07/2025
Dickinson Jonathan Elliott 2 526,948.31 263,474.16 12/09/2024 12/09/2024
Tray Thomas 11 505,190.76 45,926.43 12/12/2023 02/06/2025

Insiders marked in yellow represent long-term insiders. These are individuals who have engaged in transactions for over 3 years and have conducted at least 10 transactions or reached a cumulative turnover of $1M USD. When examining transaction clusters, we prioritize those conducted by long-term insiders for analysis.

Stock Advanced Metrics
Delta Correlation subscribe 🔒
Upper Bound of Standardized Transaction Amount (ubsta), USD 4 subscribe 🔒

4 represents the maximum expected transaction amount for a company's insiders, calculated based on historical data. It provides insight into the typical range of insider transaction amounts and helps in identifying unusually large transactions.

5 a proprietary metric reflecting the consistency of insider trading behavior within a company. A higher discipline index suggests more regular and predictable insider transactions.